Designing Effective Incentive Plans for Rare Disease Teams

While the pharmaceutical industry is still just skimming the surface when it comes to developing therapies to address the 7,000-plus known rare diseases, drug development is only half of the battle. Organizations that have successfully gained approval for their therapies in the U.S. and abroad face significant challenges when planning their commercial efforts and developing incentive strategies for the field force. To succeed, they often have to get creative.


>
Read More

Changing the Mindset: Success in Commercializing Rare Disease Drugs

There are currently only 314 FDA-approved therapies available among the roughly 7,000 rare diseases that have been identified, according to the Genetic and Rare Diseases Information Center. The global pharmaceutical industry recognizes the unmet need and the opportunity to solve the challenges associated with patients with rare diseases. Current and future pipeline assets offer the pharmaceutical industry an opportunity to bring to market the type of life-changing therapies for patients that add true value where hope is limited.


>
Read More